News Sentiment

RLMD sentiment intelligence

Relmada Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.41 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+2.1% over one week, -3.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

RELMADA THERAPEUTICS INC (RLMD) Stock Chart

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 2.1% Price confirming higher
Trend fit Trend active -3.6% over four weeks
Fair value 106.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 34
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 7
TradingKey 5
Stock Titan 4
GlobeNewswire 4
Moomoo 3
MT Newswires 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 16
Analyst action 12
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
StreetInsider Direct company coverage

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

H.C. Wainwright analyst Andres Maldonado has initiated coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating. The firm has set a price target of $12 for the stock. This news indicates a positive outlook from H.C. Wainwright on the pharmaceutical company.

Tone
Positive 76/100
Event
Analyst action
Published
18 Jun 2026 05:59
Source
StreetInsider
TradingKey Direct company coverage

Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Relmada Therapeutics Inc (RLMD), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
TradingKey
TradingKey Direct company coverage

Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on the revenue breakdown of Relmada Therapeutics Inc (RLMD). It notes that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by Relmada Therapeutics Inc. The page pri

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:09
Source
TradingKey
Insider Monkey Direct company coverage

10 Best Growth Stocks Under $30 to Buy Now

This article identifies Relmada Therapeutics Inc. (NASDAQ:RLMD) as one of the best growth stocks under $30, highlighting its strong financial position and promising clinical pipeline. The company recently reported positive Phase 2 data for NDV-01, is well-capitalized to fund oper

Tone
Positive 71/100
Event
Market update
Published
17 Jun 2026 11:19
Source
Insider Monkey
TradingKey Direct company coverage

Relmada Therapeutics Inc (RLMD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Relmada Therapeutics Inc (RLMD), noting its current valuation score of 7.88 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -6.02 and indicates that relevant data for P/B, P/S, and P/CF r

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 23:39
Source
TradingKey
TradingKey Direct company coverage

Relmada Therapeutics Inc (RLMD) Institutional Confidence

Relmada Therapeutics Inc (RLMD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 56.47%, a significant quarter-over-quarter increase of 184.86%. Steven Cohen is

Tone
Positive 70/100
Event
Market update
Published
15 Jun 2026 22:39
Source
TradingKey
Indian Pharma Post Direct company coverage

Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor

Relmada Therapeutics has appointed Michael Quirk as Senior Advisor for its Sepranolone Program, aiming to advance its central nervous system drug development. Dr. Quirk, a neuroscience veteran from Sage Therapeutics and AstraZeneca, brings over 20 years of experience in CNS trans

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 08:38
Source
Indian Pharma Post